Quick Answer
Janux Therapeutics, Inc. reported Net Income Loss of -$113.63 million for the year ending 2025.
- Janux Therapeutics, Inc. showed a decrease of -64.7% in Net Income Loss from 2024 to 2025.
- This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Janux Therapeutics, Inc.'s Net Income Loss has declined by 1,574.9%.
- Historical annual values: Fiscal year 2025: -$113.63 million | Fiscal year 2024: -$68.99 million | Fiscal year 2023: -$58.29 million | Fiscal year 2022: -$63.06 million | Fiscal year 2021: -$32.67 million | Fiscal year 2020: -$6.78 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: